Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2018-04-23
2029-04-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted.
The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of Genetic Risk of Atrial Fibrillation
NCT00412438
Quantification of Endothelial Thrombogenicity in Patients With Atrial Fibrillation
NCT02756429
Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation
NCT06954610
Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?
NCT02858518
Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
NCT06735001
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1a
Patient with atrial fibrillation and without stroke history.
Blood taken
Collection of clinical data
Blood taken
Collection of DNA
Group 1b
Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.
Blood taken
Collection of clinical data
Blood taken
Collection of DNA
Blood taken
Collection of plasma
Group 1c
Patient with atrial fibrillation and with stroke history.
Blood taken
Collection of clinical data
Blood taken
Collection of DNA
Group 2
Patients aged over 80 years old and without history of atrial fibrillation.
Blood taken
Collection of clinical data
Blood taken
Collection of DNA
Group 3
Patient with cryptogenic stroke or transient ischemic attack history before the age of 50.
Blood taken
Collection of clinical data
Blood taken
Collection of DNA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood taken
Collection of clinical data
Blood taken
Collection of DNA
Blood taken
Collection of plasma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* AF history
* Scheduled electrophysiological exploration or AF ablation
* AF/AT history
* Stroke history
* patient over 80
* ECG: sinusal rhythm
* TTE : no left atrial dilatation
* cryptogenic stroke or transient ischemic attack history before 50 yo
* No AF history
Exclusion Criteria
* patient who didn't signed consent
Group 1b
* No AF history
* pregnant women
* patient who didn't signed consent
Group 1c
* No Stroke history
* patient who didn't signed consent
Group 2
* atrial fibrillation history
* TTE : Left atria \>25cm², \> 34m/m2), FEVG \< 50%
* ECG : QRS \> 90 ms
* cardiac pathologies (excepted hypertension and valvulopathies)
* History of stroke and transient ischemic attack
* patient who didn't signed consent
Group 3
* AF history
* stroke or transient ischemic attack over 50 yo
* patient who didn't signed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service neurologie Centre hospitalier Fleyriat
Bourg-en-Bresse, , France
Service d'urgences Neurovasculaires - service de neurologie vasculaire , Hôpital Pierre Wertheimer
Bron, , France
Service de rythmologie, hôpital cardiologique Louis Pradel
Bron, , France
Service de médecine gériatrique Centre hospitalier Lyon Sud, Groupement hospitalier Sud
Pierre-Bénite, , France
Hôpital des charpennes
Villeurbanne, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A03327-46
Identifier Type: OTHER
Identifier Source: secondary_id
69HCL17_0538
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.